- Home
- BIIB vs NTR Comparison
BIIB vs NTR Comparison
Compare BIIB & NTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- NTR
- Stock Information
- Founded
- BIIB 1978
- NTR N/A
- Country
- BIIB United States
- NTR Canada
- Employees
- BIIB N/A
- NTR N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- NTR Agricultural Chemicals
- Sector
- BIIB Health Care
- NTR Industrials
- Exchange
- BIIB Nasdaq
- NTR Nasdaq
- Market Cap
- BIIB 25.1B
- NTR 22.4B
- IPO Year
- BIIB 1991
- NTR N/A
- Fundamental
- Price
- BIIB $160.85
- NTR $48.80
- Analyst Decision
- BIIB Buy
- NTR Buy
- Analyst Count
- BIIB 25
- NTR 15
- Target Price
- BIIB $258.57
- NTR $58.64
- AVG Volume (30 Days)
- BIIB 1.7M
- NTR 2.1M
- Earning Date
- BIIB 10-30-2024
- NTR 11-06-2024
- Dividend Yield
- BIIB N/A
- NTR 4.43%
- EPS Growth
- BIIB 10.05
- NTR N/A
- EPS
- BIIB 11.06
- NTR 1.48
- Revenue
- BIIB $9,607,500,000.00
- NTR $25,556,000,000.00
- Revenue This Year
- BIIB N/A
- NTR N/A
- Revenue Next Year
- BIIB N/A
- NTR $2.30
- P/E Ratio
- BIIB $14.54
- NTR $33.00
- Revenue Growth
- BIIB N/A
- NTR N/A
- 52 Week Low
- BIIB $153.62
- NTR $44.65
- 52 Week High
- BIIB $268.30
- NTR $60.87
- Technical
- Relative Strength Index (RSI)
- BIIB 37.71
- NTR 59.48
- Support Level
- BIIB $158.44
- NTR $45.15
- Resistance Level
- BIIB $165.29
- NTR $47.46
- Average True Range (ATR)
- BIIB 4.09
- NTR 0.87
- MACD
- BIIB 1.04
- NTR 0.20
- Stochastic Oscillator
- BIIB 32.51
- NTR 97.20
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About NTR Nutrien Ltd.
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with a roughly 20% market share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.